Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1978 1
1982 1
1983 1
1984 1
1985 2
1986 3
1989 1
1990 2
1993 3
1995 2
1996 4
1998 3
1999 1
2000 2
2001 1
2002 4
2003 7
2004 5
2005 8
2006 11
2007 9
2008 13
2009 9
2010 13
2011 6
2012 10
2013 3
2014 1
2015 10
2016 3
2017 6
2018 4
2019 16
2020 12
2021 17
2022 12
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Results by year

Filters applied: . Clear all
Page 1
Author Reply.
Maloney LM, Kotelnik V, Pesce K, Masterton WM, Marshall RT, Pigott G, Bialek N, Winslow J. Maloney LM, et al. Prehosp Disaster Med. 2021 Aug;36(4):500. doi: 10.1017/S1049023X21000480. Epub 2021 May 31. Prehosp Disaster Med. 2021. PMID: 34057055 No abstract available.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Coleman RL, et al. Among authors: maloney l. Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12. Lancet. 2017. PMID: 28916367 Free PMC article. Clinical Trial.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM. Lin KK, et al. Among authors: maloney l. Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13. Cancer Discov. 2019. PMID: 30425037 Free article. Clinical Trial.
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O'Malley DM, Lorusso D, Westin SN, Safra T, Herzog TJ, Marmé F, N Eskander R, Lin KK, Shih D, Goble S, Grechko N, Hume S, Maloney L, McNeish IA, Kristeleit RS. Monk BJ, et al. Among authors: maloney l. Int J Gynecol Cancer. 2021 Dec;31(12):1589-1594. doi: 10.1136/ijgc-2021-002933. Epub 2021 Sep 30. Int J Gynecol Cancer. 2021. PMID: 34593565 Free PMC article. Clinical Trial.
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL. Ledermann JA, et al. Among authors: maloney l. Lancet Oncol. 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9. Lancet Oncol. 2020. PMID: 32359490 Free PMC article.
Measuring and Modeling Visual Appearance.
Maloney LT, Knoblauch K. Maloney LT, et al. Annu Rev Vis Sci. 2020 Sep 15;6:519-537. doi: 10.1146/annurev-vision-030320-041152. Epub 2020 May 18. Annu Rev Vis Sci. 2020. PMID: 32421445 Review.
The efficiency of vision and action.
Verghese P, Maloney LT, Landy MS. Verghese P, et al. Among authors: maloney lt. Vision Res. 2015 Aug;113(Pt B):113-5. doi: 10.1016/j.visres.2015.06.003. Epub 2015 Jun 18. Vision Res. 2015. PMID: 26095677 Free article. No abstract available.
Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
Liao M, Beltman J, Giordano H, Harding TC, Maloney L, Simmons AD, Xiao JJ. Liao M, et al. Among authors: maloney l. Clin Pharmacokinet. 2022 Nov;61(11):1477-1493. doi: 10.1007/s40262-022-01157-8. Epub 2022 Sep 15. Clin Pharmacokinet. 2022. PMID: 36107395 Free PMC article. Review.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. Swisher EM, et al. Among authors: maloney l. Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29. Lancet Oncol. 2017. PMID: 27908594 Free article. Clinical Trial.
The anticipation of events in time.
Grabenhorst M, Michalareas G, Maloney LT, Poeppel D. Grabenhorst M, et al. Among authors: maloney lt. Nat Commun. 2019 Dec 20;10(1):5802. doi: 10.1038/s41467-019-13849-0. Nat Commun. 2019. PMID: 31862912 Free PMC article.
205 results